Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | LIPE | Q05469 | 4/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22171280 | 0.89 | USP30 (0.49) | USP30SCN9ATP53GPR119LIPE | |
| SCHEMBL22390264 | 0.89 | USP30 (0.48) | USP30SCN9ATP53GPR119LIPE | |
| SCHEMBL30557779 | 0.89 | USP30 (0.48) | USP30SCN9AGPR119SMN1; SMN2MEN1 | |
| SCHEMBL22390263 | 0.89 | USP30 (0.48) | USP30SCN9ATP53GPR119LIPE | |
| SCHEMBL3604174 | 0.89 | USP30 (0.48) | USP30SCN9AGPR119SMN1; SMN2MEN1 | |
| SCHEMBL22390394 | 0.88 | USP30 (0.52) | USP30SCN9AGPR119LIPEFPR2 | |
| SCHEMBL22390396 | 0.88 | USP30 (0.52) | USP30SCN9AGPR119LIPEFPR2 | |
| SCHEMBL22390458 | 0.88 | USP30 (0.48) | USP30SCN9ATP53GPR119LIPE | |
| SCHEMBL22171369 | 0.88 | USP30 (0.48) | USP30SCN9ATP53GPR119LIPE | |
| SCHEMBL22390330 | 0.88 | USP30 (0.47) | USP30SCN9ATP53GPR119DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2039695-A1 | BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | HTR2C, HTR5A, HTR2A | USP30 4815/4885SCN9A 1132/4885TP53 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.